Edition:
India

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

15.05USD
12:55am IST
Change (% chg)

$-0.12 (-0.79%)
Prev Close
$15.17
Open
$15.01
Day's High
$15.61
Day's Low
$15.01
Volume
518,231
Avg. Vol
715,986
52-wk High
$17.40
52-wk Low
$5.87

Select another date:

Fri, Feb 16 2018

BRIEF-Amicus Therapeutics Prices Underwritten Offering Of Common Stock

* AMICUS THERAPEUTICS PRICES UNDERWRITTEN OFFERING OF COMMON STOCK

BRIEF-Amicus Therapeutics Announces Public Offering Of Common Stock

* AMICUS THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

BRIEF-U.S. FDA Files NDA Under Priority Review For Migalastat

* U.S. FDA FILES NEW DRUG APPLICATION UNDER PRIORITY REVIEW FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE

BRIEF-Amicus Announces Additional Data In Pompe Disease Phase 1/2 Study

* AMICUS THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE DATA IN POMPE DISEASE PHASE 1/2 STUDY AT 14TH ANNUAL WORLDSYMPOSIUM™

BRIEF-Amicus Launches Galafold For Treatment Of Fabry Disease In Spain

* AMICUS THERAPEUTICS LAUNCHES GALAFOLD™ (MIGALASTAT) FOR TREATMENT OF FABRY DISEASE IN SPAIN Source text for Eikon: Further company coverage:

BRIEF-Amicus Therapeutics Expects 2018 Net Cash Spend Of $230 Mln To $260 Mln

* AMICUS THERAPEUTICS PROVIDES FULL-YEAR 2018 STRATEGIC OUTLOOK AND FINANCIAL GUIDANCE

BRIEF-Amicus Therapeutics Submits New Drug Application To U.S. FDA For Migalastat

* AMICUS THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE

BRIEF-Amicus Therapeutics Q3 loss per share $0.69

* Amicus therapeutics announces third quarter 2017 financial results and corporate updates

Swiss Amicus and Brazil's EMS bid for Serbian drugmaker Galenika

BELGRADE Swiss-based drugs company Amicus SRB and Brazilian pharma group EMS SA have both made binding bids for a 93 percent stake in Serbian drugmaker Galenika, Serbia's Economy Ministry said.

UPDATE 1-Swiss Amicus and Brazil's EMS bid for Serbian drugmaker Galenika

BELGRADE, Oct 4 Swiss-based drugs company Amicus SRB and Brazilian pharma group EMS SA have both made binding bids for a 93 percent stake in Serbian drugmaker Galenika, Serbia's Economy Ministry said.

Select another date: